APTA CSM registration is now open — secure the lowest rate!
By using this site, you are consenting to our use of cookies. To find out more visit our privacy policy.
Created: Sunday, January 11, 2015
Author(s): Evan T. Cohen PT, PhD, Board-Certified Neurologic Clinical Specialist; Linda Csiza, PT, DSc, Board-Certified Neurologic Clinical Specialist; Herb I. Karpatkin, PT, DSc, Board-Certified Neurologic Clinical Specialist, MSCS
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that affects approximately 400,000 people in the United States and 1 million people between 16 and 65 years of age worldwide. (1) It is a neurodegenerative pathology that can be characterized by a course of demyelination-mediated relapses and remissions, superimposed on gradual neurologic deterioration, resulting in a clinical course that is unpredictable in progression and severity. (1)
Join APTA to get unlimited access to content including evidence-based research, guidance on payment changes, and other resources to help you thrive. Learn more about membership benefits.
Already a member? Log in